Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | HPD | P32754 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Afloqualone SCHEMBL29540781 | 1.00 | PDE4D (1.00) | PDE4DALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL10735755 | 0.91 | PDE4D (0.83) | PDE4DALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL18687883 | 0.88 | PDE4D (0.78) | PDE4DALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL10739746 | 0.87 | PDE4D (0.77) | PDE4DALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL10741182 | 0.86 | PDE4D (0.76) | PDE4DALDH1A1KDM4EHPGDHPD | |
| SCHEMBL10742868 | 0.86 | PDE4D (0.76) | PDE4DALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL10737618 | 0.85 | PDE4D (0.74) | PDE4DALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL10711517 | 0.85 | PDE4D (0.74) | PDE4DALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL10709171 | 0.85 | PDE4D (0.74) | PDE4DALDH1A1KDM4EHPGDMAPT | |
| Afloqualone SCHEMBL1550492 | 0.85 | PDE4D (0.72) | PDE4DALDH1A1KDM4EHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 847 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163379-A1 | METHOD FOR DIFFERENTIATING HEMATOPOIETIC STEM/PROGENITOR CELLS INTO NK CELLS | HEMACELL BIOTECHNOLOGY INC. (CN) | 2025-05-22 | — | — | US | claimed |
| CN-118786209-A | Method for differentiating hematopoietic stem/progenitor cells into NK cells | 苏州血霁生物科技有限公司 | 2024-10-15 | — | — | CN | claimed |
| WO-2023165503-A1 | METHOD FOR DIFFERENTIATING HEMATOPOIETIC STEM/PROGENITOR CELLS INTO NK CELLS | 苏州血霁生物科技有限公司 | 2023-09-07 | — | — | WO | claimed |
| US-20220151955-A1 | KETAMINE FOR THE TREATMENT OF POSTPARTUM SYMPTOMS AND DISORDERS | THE KETAMINE RESEARCH FOUNDATION | 2022-05-19 | — | — | US | claimed |
| EP-3923920-A1 | KETAMINE FOR THE TREATMENT OF POSTPARTUM SYMPTOMS AND DISORDERS | The Ketamine Research Foundation (US) | 2021-12-22 | — | — | EP | claimed |
| US-20210113493-A1 | KETAMINE FOR THE TREATMENT OF MENSTRUALLY RELATED SYMPTOMS | WOLFSON PHILIP E (US) | 2021-04-22 | — | — | US | claimed |
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | claimed |
| WO-2021026232-A1 | KETAMINE FOR THE TREATMENT OF POSTPARTUM SYMPTOMS AND DISORDERS | THE KETAMINE RESEARCH FOUNDATION (US) | 2021-02-11 | — | — | WO | claimed |
| WO-2020006606-A1 | A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME | HELIUM 3 RESOURCES PTY LTD (AU) | 2020-01-09 | — | — | WO | claimed |
| EP-3548014-A1 | KETAMINE FOR THE TREATMENT OF MENSTRUALLY RELATED SYMPTOMS | Wolfson, Philip, E. (US) | 2019-10-09 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| CN-1242934-A | Toxinless chemical for rat eradication | ZHOU LIANGYONG (CN) | 2000-02-02 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| EP-0208335-B1 | USE OF A QUINAZOLINONE IN THE PREPARATION OF AN ANTI-VERTIGO DRUG AND PHARMACEUTICAL COMPOSITION | Tanabe Seiyaku Co., Ltd. (JP) | 1992-01-22 | — | — | EP | claimed |
| US-4721714-A | NERVOUS SYSTEM DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 1988-01-26 | — | — | US | claimed |
| EP-0208335-A2 | Use of a quinazolinone in the preparation of an anti-vertigo drug and pharmaceutical composition | Tanabe Seiyaku Co., Ltd. (JP) | 1987-01-14 | — | — | EP | claimed |
| US-3966731-A | CENTRAL MUSCLE RELAXANTS, TRANQUILIZERS, ANTICONVULSANTS, ANALGESICS, ANTIINFLAMMATORY | TANABE SEIYAKU CO., LTD. (JA) | 1976-06-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151955-A1 | KETAMINE FOR THE TREATMENT OF POSTPARTUM SYMPTOMS AND DISORDERS | OXTR, PNISR, KCNQ5 | PDE4D 2476/4885ALDH1A1 3471/4885KDM4E 197/4885 |
| US-20210113493-A1 | KETAMINE FOR THE TREATMENT OF MENSTRUALLY RELATED SYMPTOMS | KCNK5, KCNQ5, KCND2 | PDE4D 2020/4885ALDH1A1 3782/4885KDM4E 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.